Proceedings from the 2ndNext Gen Therapies for Systemic Juvenile Idiopathic Arthritis and Macrophage Activation Syndrome symposium held on October 3-4, 2019

NextGen 2019 Participants

Research output: Contribution to journalArticle

Abstract

For reasons poorly understood, and despite the availability of biological medications blocking IL-1 and IL-6 that have markedly improved overall disease control, children with Systemic Juvenile Idiopathic Arthritis (SJIA) are now increasingly diagnosed with life-threatening chronic complications, including hepatitis and lung disease (SJIA-LD). On October 3-4, 2019, a two-day meeting, NextGen Therapies for Systemic Juvenile Idiopathic Arthritis (SJIA) & macrophage activation syndrome (MAS) organized by the Systemic JIA Foundation (www.systemicjia.org/) in Washington, DC brought together scientists, clinicians, parents and FDA representatives with the objectives (1) to integrate clinical and research findings in MAS and SJIA-LD, and (2) to develop a shared understanding of this seemingly new pulmonary complication of SJIA. The current manuscript summarizes discussions and conclusions of the meeting.

Original languageEnglish (US)
Article number53
JournalPediatric Rheumatology
Volume18
DOIs
StatePublished - Jul 15 2020

Keywords

  • Alveolar macrophages
  • Hemophagocytic lymphohistiocytosis
  • Interferonopathy
  • Interstitial lung disease
  • Macrophage activation syndrome
  • Pulmonary alveolar proteinosis
  • Systemic juvenile idiopathic arthritis

Fingerprint Dive into the research topics of 'Proceedings from the 2<sup>nd</sup>Next Gen Therapies for Systemic Juvenile Idiopathic Arthritis and Macrophage Activation Syndrome symposium held on October 3-4, 2019'. Together they form a unique fingerprint.

  • Cite this